FY2020 · ended Dec 31, 2020 · Revenue $0, -100.0% YoY · Filed Mar 22, 2022
Phio Pharmaceuticals Corp (PHIO) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$8.0 million.
Revenue
$0
-100.0% vs prior year
Net income
$-8.70M
-21.7% vs prior year
Operating cash flow (TTM)
$-12.40M
-70.5% vs year-ago TTM
Free cash flow (TTM)
$-12.40M
-70.2% vs year-ago TTM
EPS
$-9.08
+80.6% vs prior year
Dividend per share
None
Shares outstanding
11.62M
+143.1% vs prior year
Net cash
$5.38M
FY 2024
Operating margin
-42795.2%
FY 2019
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PHIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- King Of Prussia, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1533040
- Former names
- RXi Pharmaceuticals Corp (until Nov 14, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$9.2M | -$7.4M | -$10.8M | -$11.5M | -$13.5M |
| Net income | -$8.7M | -$7.2M | -$10.8M | -$11.5M | -$13.3M |
| Diluted EPS | — | -$9.08 | -$46.76 | -$10.10 | — |
| Operating cash flow | -$8.0M | -$7.1M | -$10.7M | -$12.1M | -$11.9M |
| Free cash flow | -$8.0M | -$7.1M | -$10.8M | -$12.2M | -$11.9M |
| Total assets | $21.5M | $5.7M | $9.4M | $12.8M | $25.2M |
| Total liabilities | $1.3M | $1.0M | $1.6M | $2.0M | $3.2M |
| Stockholders' equity | $20.1M | $4.7M | $7.7M | $10.8M | $21.9M |
| Cash and investments | $21.0M | $5.4M | — | — | — |
| Total debt | — | $0 | $35,000 | $170,000 | $295,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 28, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| ARS | Annual report to shareholders | Aug 14, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
All 892 Phio Pharmaceuticals Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.